A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: Development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs

Journal of Pharmaceutical Sciences

Volumn 101, Issue 4, 2012, Pages 1462-1474

  Quinn, Kevin ^a   Gullapalli, Rampurna Prasad ^a   Merisko liversidge, Elaine ^b   Goldbach, Erich ^a   Wong, Angelina ^a   Liversidge, Gary G ^b   Hoffman, Wherly ^a   Sauer, John michael ^a   Bullock, John ^b   Tonn, George ^a  

^a ELAN PHARMACEUTICALS   (United States)

^b Alkermes   (United States)

Author keywords

Alzheimer's disease; Bioavailability; Biopharmaceutics Classification System (BCS); Crystallinity; Dissolution; Food effects; Gamma secretase inhibitor; Oral drug delivery; Particle size; Pharmacokinetics; Solubility

Indexed keywords

ELND006; GAMMA SECRETASE INHIBITOR; GELATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; FOOD INTAKE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PARTICLE SIZE; SUSPENSION;

EID: 84857502649     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23034     Document Type: Article

References (66)

1. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
2. Pollack SJ, Lewis H. 2005. γ-Secretase inhibitor for Alzheimer's disease: Challenges of a promiscuous protease. Curr Opin Investig Drugs 6:35-47.
3. Brigham E, Quinn K, Kwong G, Willits C, Goldbach E, Motter R, Lee M, Hu K, Wallace W, Kholodenko D, Tang-Tanaka P, Ni H, Hemphill S, Chen XH, Eichenbaum T, Ruslim L, Nguyen L, Santiago P, Liao A, Bova M, Probst G, Dappen M, Jagodzinski J, Basi G, Ness D. 2010. Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration. Presentation: P3-320 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD). Honolulu, Hawaii. July 10-15, 2010.
4. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
5. Lobenberg R, Amidon GL. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12.
6. Stegemann S, Leveiller F, Franchi D, Dejong H, Linden H. 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31:249-261.
7. Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Del Rev 60:717-733.
8. Dahan A, Amidon GL. 2010. Provisional BCS classification of the leading oral drugs on the global market. In Donald J. Abraham, David P. Rotella (eds), Burger's medicinal chemistry, drug discovery and development. 7th Ed. John Wiley & Sons, Inc., Hoboken, New Jersey, pp 353-366.
9. Bramer SL, Forbes WP. 1999. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 37:13-23.
10. Singh BN. 1999. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213-255.
11. Fahr A, Liu X. 2007. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 4:403-416.
12. Elder DP. 2011. Effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs). Pharm OutsourcingMarch/April 2011 56-61.
13. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
14. Singh BN. 2005. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally acrive drugs administered as immediate-release formulations. Drug Dev Res 65:55-75.
15. Gokhale R. 2010. Food effects on drug formulation performance in vivo. Drug Deliv Technol 6:62-72.
16. Fleisher D, Li C, Zhou Y, Pao L, Karim A. 1999. Drug, meal, and formulation interactions influencing drug absorption after oral administration: Clinical implications. Clin Pharmacokinet 36:233-254.
17. Welling PG. 1989. Effects of food on drug absorption. Pharmacol Ther 43:425-441.
18. Marathe PH, Greene DS, Kollia GD, Barbhaiya RH. 1998. Evaluation of the effect of food on the pharmacokinetics of avitriptan. Biopharm Drug Dispos 19:381-394.
19. Charman WN, Porter CJ, Mithani S, Dressman JB. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
20. Maka DA, Murphy LK. 2008. Drug-nutrient interactions: A review. AACN Clin Issues 11:580-589.
21. Lentz KA, Quitko M, Morgan DG, Grace JE Jr., Gleason C, Marathe PH. 2007. Development and validation of a preclinical food effect model. J Pharm Sci 96:459-472.
22. Bastin RJ, Bowker MJ, Slater BJ. 2000. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org Proc Res Dev 4:427-435.
23. Agharkar S, Lindenbaum S, Higuchi T. 1976. Enhancement of solubility of drug salts by hydrophilic counter-ions: Properties of organic salts of an anti-malarial drug. J Pharm Sci 65:747-749.
24. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59:603-616.
25. Kumar L, Amin A, Bansai AK. 2008. Salt selection in drug development. Pharm Technol 3:128-142.
26. Nokhodchi A, Hentzschel CM, Leopold CS. 2011. Drug release from liquid solid systems: Speed it up, slow it down. Expert Opin Drug Deliv 8:191-205.
27. DiNunzio JC, Miller DA, Yang W, McGinty JW, Williams RO. 2008. Amorphous compositions using concentrating enhancing polymers for improved bioavailabilty of itraconazole. Mol Pharm 5:968-980.
28. Serajuddin ATM. 1999. Solid dispersion of poorly water soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
29. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
30. Dannenfelser R, He H, Oshi Y, Bateman S, Serajuddin ATM. 2004. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 93:1165-1175.
31. Bildstein L, Dubernet C, Couvreur P. 2011. Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 63:3-23.
32. Gopal S, Gassmann-Mayer C, Palumbo MN, Samtani R, Shiwach R, Alphs L. 2010. Practical guidance for dosing and switching laperidine palmitate treatment in patients with schizophrenia. Curr Med Res Opin 26:377-387.
33. Stella VJ, Nti-Addae KW. 2007. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59:677-694.
34. Merisko-Liversidge E, Liversidge GG. 2011. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Del Rev 63:427-440.
35. Timpe C. 2010.Drug solubilization strategies applying nanoparticulate formulation and solid dispersion approaches, drug development. Pharm Rev 13:12-21.
36. Pu X, Sun J, Li M, He Z. 2009. Formulation of nanosuspensions as a new approach for the delivery of poorly water soluble drugs. Curr Nanoscience 5:417-427.
37. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van Den Mooter G. 2008. Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur J Pharm Sci 35:344-353.
38. Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631-644.
39. Kipp JE. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284:109-122.
40. Liversidge GG, Cundy KC. 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125:91-97.
41. Gullapalli RP. 2010. Soft gelatin capsules (softgels). J Pharm Sci 99:4107-4148.
42. Vonderscher J, Meinzer A. 1994. Rationale for the development of sandimmune neoral. Transplant Proc 26:2925-2927.
43. Mueller EA, Kovarik JM, Van Bree JB, Tetzloff W, Grevel J, Kutz K. 1994. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 11:301-304.
44. Johnson BF, Smith G, French J. 1977. The comparability of dosage regimens of lanoxin tablets and lanoxicaps. Br J Clin Pharmacol 4:209-211.
45. Mallis GI, Schmidt DH, Lindenbaum J. 1975. Superior bioavailability of digoxin solution in capsules. Clin Pharmacol Ther 18:761-768.
46. Laza-Knoeer AL, Gref R, Couvreur P. 2010. Cyclodextrins for drug delivery. J Drug Targeting 18:645-656.
47. Jansook P, Kurkov SV, Loftsson T. 2010. Cyclodextrins as solubilizers: Formation of complex aggregates. J Pharm Sci 99:719-729.
48. Loftsson T, Brewster ME. 2010. Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol 62:1607-1621.
49. Stella VJ, He Q. 2008. Cyclodextrins. Toxicol Pathol 36:30-42.
50. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, Storey D. 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A beagle dog model predicts improved bioavailability and diminished food effect on absorption in humans. Int J Pharm 285:135-146.
51. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111:56-64.
52. Cook CS, Hauswald CL, Grahn AY, Kowalski K, Karim A, Koch R, Schoenhard GL, Oppermann JA. 1990. Suitability of the dog as an animal model for evaluating theophylline absorption and food effects from different formulations. Int J Pharm 60:125-132.
53. FDA Guidance for Industry. 2002. Food-effect bioavailability and fed bioequivalence studies.
54. Rowland M, Tozer TN. 2011. Clinical pharmacokinetics and pharmacodynamics: Concepts and applications. 4th ed. New York, New York: Wolters Kluwer Health/Lippincott Williams & Wilkins.
55. Keselman HJ, Algina J, Kowalchuk RK, Wolfinger RD. 1998. A comparison of two approaches for selecting covariance structures in the analysis of repeated measurements. Commun Stat: Simulations Comput 27:591-604.
56. Kenward MG, Roger JH. 1997. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53:983-997.
57. Serajuddin ATM, Sheen PC, Augustine MA. 1986. Water migration from soft gelatin capsule shell to fill material and its effect on drug solubility. J Pharm Sci 75:62-64.
58. Groves MJ, Bassett B, Sheth V. 1984. The solubility of 17 β-oestradiol in aqueous polyethylene glycol 400. J Pharm Pharmacol 36:799-802.
59. Merisko-Liversidge E, Liversidge GG. 2008. Drug nanoparticles: Formulating poorly water-soluble compounds. Tox Path 36:43-48.
60. Roy A, Winnike R, Long S, Rhodes C, Bao Z, Robertson G. 2001. Development of a soft gelatin capsule formulation of a poorly soluble compound X using a self emulsifying delivery system. In Oral drug absorption: A renaissance;Gattefossé BT, Ed. Saint-Priest Cedex, France: Gattefossé Corporation, pp 141-149.
61. Aungst BJ, Nguyen NH, Rogers NJ, Rowe SM, Hussain MA, White SJ, Shum L. 1997. Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int J Pharm 156:79-88.
62. Stanley JP. 1986. Soft gelatin capsules. In The theory and practice of industrial pharmacy;Lachman L, Lieberman HA, Kanig JL, Eds. 3rd ed. Philadelphia: Lea and Febiger, pp 398-412.
63. Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
64. Nernst W. 1904. Theorie der Reaktiongeschwindigkeit in heterogenen Systemen. Z Phys Chem 47:52-55.
65. Brunner E. 1904. Reactionsgeschwindigkeit in heterogenen Systemen. Z Phys Chem 47:56-102.
66. Dokoumetzidis A, Macheras P. 2006. A century of dissolution research: From Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321:1-11.